Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Gains from Investment Securities (2016 - 2025)

Rocket Pharmaceuticals' Gains from Investment Securities history spans 9 years, with the latest figure at $16.0 million for Q4 2024.

  • For Q4 2024, Gains from Investment Securities rose 7.94% year-over-year to $16.0 million; the TTM value through Jun 2025 reached $20000.0, changed N/A, while the annual FY2024 figure was $16.0 million, 7.94% up from the prior year.
  • Gains from Investment Securities for Q4 2024 was $16.0 million at Rocket Pharmaceuticals, up from $14.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $20.2 million in Q1 2020 and bottomed at -$19.6 million in Q2 2020.
  • The 5-year median for Gains from Investment Securities is $3.5 million (2021), against an average of $4.9 million.
  • The largest YoY upside for Gains from Investment Securities was 8860.48% in 2023 against a maximum downside of 97.85% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $614000.0 in 2020, then skyrocketed by 747.39% to $5.2 million in 2021, then surged by 140.76% to $12.5 million in 2022, then rose by 18.66% to $14.9 million in 2023, then rose by 7.94% to $16.0 million in 2024.
  • Per Business Quant, the three most recent readings for RCKT's Gains from Investment Securities are $16.0 million (Q4 2024), $14.9 million (Q4 2023), and $269314.0 (Q2 2023).